Non-alcoholic fatty liver disease (NAFLD) is a prevalent and progressive liver disease, affecting approximately 25% of the global population. This article provides a comprehensive overview of NAFLD, its pathophysiology, diagnosis, and management.
NAFLD is characterized by the accumulation of excess fat in the liver, unrelated to alcohol consumption. It is closely associated with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma.
NAFLD is often asymptomatic and may be incidentally diagnosed during routine blood tests or imaging studies. Liver biopsy remains the gold standard for diagnosing NASH and assessing fibrosis. However, non-invasive tests like elastography and serum biomarkers are increasingly used due to their safety and convenience.
The primary management strategy for NAFLD involves lifestyle modifications, including weight loss, healthy diet, and regular exercise. Pharmacological interventions are considered for patients with NASH or significant fibrosis. Currently, Vitamin E and Pioglitazone have shown some benefits in these patients. Several new drugs targeting different pathophysiological pathways are under investigation.
Healthcare professionals play a crucial role in the early detection and management of NAFLD. They should educate patients about the importance of lifestyle changes and monitor them regularly for disease progression. Multidisciplinary approach involving hepatologists, dietitians, and endocrinologists may be beneficial in managing this complex disease.
NAFLD is a significant global health issue with potential serious outcomes. Understanding its pathophysiology, diagnosis, and management strategies is essential for healthcare professionals to effectively manage this disease and prevent its progression.
1.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
2.
Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?
3.
Chemo causes lasting physical decline in breast cancer survivors
4.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
5.
BMI is linked to heart damage from chemotherapy in breast cancer patients.
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Rehabilitation Following Bone Marrow Functional Suppression: Clinical Strategies and Advances
3.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
4.
Strategic Breakthroughs in Oncology in Clinical Decision-Making
5.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Early warning sings of camcer that need medical attention
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation